Strumento inattivo

Altre lingue PHOX BIOT26 Nasdaq

Azioni

PBAXU

US71902K2042

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024	08/07
CERo Therapeutics Holdings, Inc.(NasdaqGM:CERO) added to S&P TMI Index	24/06
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236	13/06
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236	06/06
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236	06/06
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders	15/05
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes	30/04
PHOX BIOT26 : CERo Therapeutics Investor Presentation	25/04
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Top Premarket Decliners	11/03
Top Premarket Gainers	08/03
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients	07/03
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	07/03
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.	23/02
Top Premarket Decliners	20/02
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	15/02
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer	15/02
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes	15/02
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer	15/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PHOX BIOT26 Nasdaq

Azioni

PBAXU

US71902K2042

Altre lingue

Filtri